| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2016 | Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer | Chiang N.-J.; CHIUN HSU ; Chen J.-S.; Tsou H.-H.; Shen Y.-Y.; Chao Y.; Chen M.-H.; Yeh T.-S.; Shan Y.-S.; Huang S.-F.; Chen L.-T. | Scientific Reports | 16 | 14 | |
| 2021 | Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study | Chiu T.-J.; Su Y.-Y.; SHIH-HUNG YANG ; Li C.-P.; Bai L.-Y.; Chiang N.-J.; Chuang S.-C.; Shan Y.-S.; Chan D.-C.; Chen L.-T.; Yen C.-J.; Peng C.-M.; Chen Y.-Y.; Chen J.-S.; Chou W.-C. | Therapeutic Advances in Medical Oncology | 2 | 4 | |
| 2020 | A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma–TCOG T1211 study | Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; SHIH-HUNG YANG ; Hsiao H.-H.; Shen W.-C.; CHIUN HSU ; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. | European Journal of Cancer | 7 | 7 | |
| 2020 | Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study | Chiang N.-J.; Chen M.-H.; SHIH-HUNG YANG ; CHIUN HSU ; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. | Liver International | 5 | 5 | |
| 2021 | Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors | Shiah H.-S.; Chiang N.-J.; CHIA-CHI LIN ; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T. | Oncologist | 0 | 0 |
